Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
...
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Study of LC23-1306 in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 113
- Registration Number
- NCT01526577
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Pharmacodynamic Study With Ticagrelor in African American Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT01523392
- Locations
- 🇺🇸
Research Site, Beaumont, Texas, United States
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 53
- Registration Number
- NCT01523366
- Locations
- 🇺🇸
Research Site, Linden, New Jersey, United States
Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 20
- Registration Number
- NCT01511471
- Locations
- 🇬🇷
Cardiology Department Patras University Hospital, Rio, Achaia, Greece
🇬🇷Agios Andreas General Hospital, Nephrology Department, Patras, Achaia, Greece
Rapid Activity of Platelet Inhibitor Drugs Study
- Conditions
- Interventions
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Careggi Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01510171
- Locations
- 🇮🇹
Careggi Hospital, Florence, Italy
Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT01504906
- Locations
- 🇺🇸
Research site, Overland Park, Kansas, United States
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2012-04-10
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 50
- Registration Number
- NCT01463163
- Locations
- 🇬🇷
Cardiology Department Patras University Hospital, Rio, Achaia, Greece
Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 70
- Registration Number
- NCT01456364
- Locations
- 🇩🇪
Deutsches Herzzentrum, München, Bavaria, Germany
🇩🇪Klinikum der Ludwig-Maximilians-Universität München, München, Bavaria, Germany
🇭🇺Heart Center Balatonfüred, Dept. of Cardiology, Balatonfüred, Hungary
Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- Cardiology Research UBC
- Target Recruit Count
- 70
- Registration Number
- NCT01373411
- Locations
- 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 44
- Registration Number
- NCT01360437
- Locations
- 🇬🇷
Cardiology Department Patras University Hospital, Rio, Patras, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.